Phase I,open label study to assess the safety and tolerability of ZD6474 [vandetanib] in combination with 5-fluorouracil, leucovorin [folinic acid] and oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma

Trial Profile

Phase I,open label study to assess the safety and tolerability of ZD6474 [vandetanib] in combination with 5-fluorouracil, leucovorin [folinic acid] and oxaliplatin (mFOLFOX6) as first and second line therapy in patients with advanced colorectal adenocarcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Vandetanib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 24 Jan 2008 The expected completion date for this trial is now 1 Mar 2008.
    • 10 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top